65 related articles for article (PubMed ID: 20386533)
1. Documentation of oral versus intravenous chemotherapy plans in patients with metastatic non-small-cell lung cancer.
Greer JA; Lennes IT; Gallagher ER; Temel JS; Pirl WF
J Oncol Pract; 2014 Mar; 10(2):e103-6. PubMed ID: 24474823
[TBL] [Abstract][Full Text] [Related]
2. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).
Shi Y; Au JS; Thongprasert S; Srinivasan S; Tsai CM; Khoa MT; Heeroma K; Itoh Y; Cornelio G; Yang PC
J Thorac Oncol; 2014 Feb; 9(2):154-62. PubMed ID: 24419411
[TBL] [Abstract][Full Text] [Related]
3. EGFR-activating mutations correlate with a Fanconi anemia-like cellular phenotype that includes PARP inhibitor sensitivity.
Pfäffle HN; Wang M; Gheorghiu L; Ferraiolo N; Greninger P; Borgmann K; Settleman J; Benes CH; Sequist LV; Zou L; Willers H
Cancer Res; 2013 Oct; 73(20):6254-63. PubMed ID: 23966292
[TBL] [Abstract][Full Text] [Related]
4. Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer.
Willers H; Azzoli CG; Santivasi WL; Xia F
Cancer J; 2013; 19(3):200-7. PubMed ID: 23708066
[TBL] [Abstract][Full Text] [Related]
5. Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer.
Markova B; Hähnel PS; Kasper S; Herbertz S; Schuler M; Breitenbuecher F
J Cancer Res Clin Oncol; 2012 Apr; 138(4):545-54. PubMed ID: 22203472
[TBL] [Abstract][Full Text] [Related]
6. [Classification and regression tree analysis of clinical patterns to predict the survival of patients with advanced non-small cell lung cancer treated with erlotinib].
Liu Y; Guo J; Wang Y; Yang J; Wang Z
Zhongguo Fei Ai Za Zhi; 2011 Oct; 14(10):785-9. PubMed ID: 22008108
[TBL] [Abstract][Full Text] [Related]
7. [Classification and regression tree analysis of clinical patterns that predict survival in 127 Chinese patients with advanced non-small cell lung cancer treated by gefitinib who failed to previous chemotherapy].
Wang Z; Guo J; Wang Y; Liu Y; Yang J
Zhongguo Fei Ai Za Zhi; 2011 Sep; 14(9):699-703. PubMed ID: 21924034
[TBL] [Abstract][Full Text] [Related]
8. Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials.
Ibrahim EM
Ann Thorac Med; 2010 Jul; 5(3):153-60. PubMed ID: 20835310
[TBL] [Abstract][Full Text] [Related]
9. EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
Soria JC; Mok TS; Cappuzzo F; Jänne PA
Cancer Treat Rev; 2012 Aug; 38(5):416-30. PubMed ID: 22119437
[TBL] [Abstract][Full Text] [Related]
10. First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Neal JW; Sequist LV
Clin Adv Hematol Oncol; 2010 Feb; 8(2):119-26. PubMed ID: 20386533
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
Pao W; Miller VA
J Clin Oncol; 2005 Apr; 23(11):2556-68. PubMed ID: 15767641
[TBL] [Abstract][Full Text] [Related]
12. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Di Maio M; Gridelli C; Normanno N; Perrone F; Ciardiello F
J Cell Physiol; 2005 Dec; 205(3):355-63. PubMed ID: 15895392
[TBL] [Abstract][Full Text] [Related]
13. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Gridelli C; De Marinis F; Di Maio M; Cortinovis D; Cappuzzo F; Mok T
Lung Cancer; 2011 Mar; 71(3):249-57. PubMed ID: 21216486
[TBL] [Abstract][Full Text] [Related]
14. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
